ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Risankizumab

First Posted Date: 2019-09-25

Last Posted Date: 2023-11-27

Lead Sponsor: AbbVie

Target Recruit Count: 244

Registration Number: NCT04102007

Locations: 🇬🇧
Northern Care Alliance NHS Group /ID# 213873, Salford, United Kingdom
🇺🇸
Burke Pharmaceutical Research /ID# 225023, Hot Springs, Arkansas, United States
🇺🇸
Arkansas Research Trials /ID# 225497, North Little Rock, Arkansas, United States

and more 54 locations

A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

Phase 3

Active, not recruiting

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: Venetoclax
Drug: Azacitidine

First Posted Date: 2019-09-25

Last Posted Date: 2024-08-06

Lead Sponsor: AbbVie

Target Recruit Count: 112

Registration Number: NCT04102020

Locations: 🇺🇸
The John Theurer Cancer /ID# 215191, Hackensack, New Jersey, United States
🇺🇸
University of California, Los Angeles /ID# 219149, Los Angeles, California, United States
🇺🇸
Duplicate_Rush University Medical Center /ID# 218815, Chicago, Illinois, United States

and more 153 locations

IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Azacitidine
Drug: IMGN632
Drug: Venetoclax

First Posted Date: 2019-09-11

Last Posted Date: 2024-12-17

Lead Sponsor: AbbVie

Target Recruit Count: 218

Registration Number: NCT04086264

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

and more 28 locations

Real-World Experience Study of Elagolix For the Treatment of Endometriosis in Canada

Completed

Conditions: Endometriosis

First Posted Date: 2019-09-06

Last Posted Date: 2022-09-28

Lead Sponsor: AbbVie

Target Recruit Count: 100

Registration Number: NCT04080856

Locations: 🇨🇦
IWK Health Center /ID# 213066, Halifax, Nova Scotia, Canada
🇨🇦
Strand Clinic /ID# 213567, St. John's, Newfoundland and Labrador, Canada
🇨🇦
Jessima R&D Inc. /ID# 212943, Lasalle, Quebec, Canada

and more 15 locations

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Phase 3

Recruiting

Conditions: Chronic Kidney Disease (CKD)
Secondary Hyperparathyroidism (SHPT)

Interventions: Drug: Paricalcitol

First Posted Date: 2019-08-22

Last Posted Date: 2024-06-25

Lead Sponsor: AbbVie

Target Recruit Count: 16

Registration Number: NCT04064827

Locations: 🇺🇸
Seattle Children's Hospital /ID# 162861, Seattle, Washington, United States
🇺🇸
Boston Children's Hospital /ID# 162863, Boston, Massachusetts, United States
🇺🇸
Duplicate_Levine Children's Specialty Center- Charlotte /ID# 216057, Charlotte, North Carolina, United States

and more 10 locations

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Phase 1

Active, not recruiting

Conditions: Myeloproliferative Neoplasm

Interventions: Drug: Navitoclax
Drug: Ruxolitinib
Drug: Celecoxib

First Posted Date: 2019-08-01

Last Posted Date: 2024-06-18

Lead Sponsor: AbbVie

Target Recruit Count: 85

Registration Number: NCT04041050

Locations: 🇺🇸
Providence - St. Jude Medical Center /ID# 242558, Fullerton, California, United States
🇺🇸
Moores Cancer Center at UC San Diego /ID# 229584, La Jolla, California, United States
🇺🇸
City of Hope /ID# 239769, Duarte, California, United States

and more 39 locations

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

Phase 3

Completed

Conditions: Functional Constipation
Irritable Bowel Syndrome With Constipation

Interventions: Drug: Placebo
Drug: Linaclotide

First Posted Date: 2019-07-19

Last Posted Date: 2024-11-26

Lead Sponsor: AbbVie

Target Recruit Count: 438

Registration Number: NCT04026113

Locations: 🇺🇸
Medclinical Research Partners LLC/ Foundation Pediatrics /ID# 232783, East Orange, New Jersey, United States
🇺🇸
University of New Mexico /ID# 233011, Albuquerque, New Mexico, United States
🇺🇸
The Children's Hospital at Montefiore /ID# 232638, Bronx, New York, United States

and more 112 locations

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

Phase 2

Conditions: Neovascular Age-related Macular Degeneration
Wet Macular Degeneration

Interventions: Genetic: RGX-314

First Posted Date: 2019-06-27

Last Posted Date: 2024-06-17

Lead Sponsor: AbbVie

Target Recruit Count: 865

Registration Number: NCT03999801

Locations: 🇺🇸
Retinal Research Institute, LCC, Phoenix, Arizona, United States
🇺🇸
Sierra Eye Associates, Reno, Nevada, United States
🇺🇸
MidAtlantic Retina, Philadelphia, Pennsylvania, United States

and more 6 locations

A Study to Describe the Safety and Effectiveness of Venetoclax in Acute Myeloid Leukemia (AML) Patients (REVIVE Study)

Suspended

Conditions: Acute Myeloid Leukemia

First Posted Date: 2019-06-17

Last Posted Date: 2024-01-17

Lead Sponsor: AbbVie

Target Recruit Count: 100

Registration Number: NCT03987958

Locations: 🇮🇱
Rambam Health Care Campus /ID# 213355, Haifa, H_efa, Israel
🇮🇱
Rabin Medical Center /ID# 213343, Haifa, H_efa, Israel
🇮🇱
HaEmek Medical Center /ID# 213370, Afula, HaDarom, Israel

and more 9 locations

Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis

Active, not recruiting

Conditions: Chronic Plaque Psoriasis

First Posted Date: 2019-06-11

Last Posted Date: 2024-06-20

Lead Sponsor: AbbVie

Target Recruit Count: 2439

Registration Number: NCT03982394

Locations: 🇯🇵
Nagoya City University Hospital /ID# 213363, Nagoya shi, Aichi, Japan
🇪🇸
Hospital General Universitario Gregorio Maranon /ID# 231664, Madrid, Spain
🇦🇺
Premier Specialist /ID# 218158, Kogarah, New South Wales, Australia

and more 299 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy